Atossa Therapeutics, Inc.
NasdaqCM:ATOS Rapport sur les actions
Capitalisation boursière : US$203.7m
Atossa Therapeutics Croissance future
Future contrôle des critères 0/6 Les bénéfices de Atossa Therapeutics devraient diminuer de 10.4% par an tandis que son chiffre d'affaires annuel devrait croître de 64.4% par an. Le BPA devrait croître de en hausse de 64.8% par an.
Informations clés
-10.4%
Taux de croissance des bénéfices
64.8%
Taux de croissance du BPA
Biotechs croissance des bénéfices 27.3% Taux de croissance des recettes 64.4% Rendement futur des capitaux propres n/a Couverture par les analystes Low
Dernière mise à jour 12 Nov 2024
Mises à jour récentes de la croissance future
Forecast to breakeven in 2026 Aug 13
No longer forecast to breakeven Jun 10
No longer forecast to breakeven May 15
Forecast to breakeven in 2026 Dec 31
Price target decreased by 7.5% to US$4.63 May 24
Price target decreased to US$5.00 Nov 16
Afficher toutes les mises à jour
New major risk - Revenue and earnings growth Nov 12
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth Nov 12
Atossa Therapeutics: Important News, But The Company Still Has A Long Way To Go Nov 08
Atossa Therapeutics Reports Positive Karisma-Endoxifen Trial Results Nov 05
Atossa Therapeutics, Inc Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer Nov 02
Atossa Therapeutics Grants Additional Patent Protection for Endoxifen Aug 28
Atossa Therapeutics, Inc. and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer Aug 21
Forecast to breakeven in 2026 Aug 13
Atossa Therapeutics Completes Enrollment of 80Mg Pharmacokinetic Run-In Cohort in Phase 2 Evangeline Clinical Trial Evaluating (Z)-Endoxifen as A Neoadjuvant Treatment for Er+ / Her2- Breast Cancer Jul 22
Atossa Therapeutics, Inc. Appoints Heather Rees as Chief Financial Officer Jul 03
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth Jul 01
Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer Jun 28
No longer forecast to breakeven Jun 10
Atossa Therapeutics, Inc. Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model May 29
Atossa Therapeutics, Inc. Announces Last Patient, Last Dose in Its Phase 2 Karisma-Endoxifen Clinical Trial May 16
No longer forecast to breakeven May 15
Atossa Therapeutics, Inc., Annual General Meeting, Jun 27, 2024 May 14
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Announces I-SPY 2 Clinical Trial to Evaluate (Z-Endoxifen in Combination with Abemaciclib (VERZENIO®?) in Women with ER+/HER2- Breast Cancer Apr 15
Atossa Therapeutics, Inc. Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen Apr 10
New minor risk - Profitability Apr 02
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for A U.S. Breast Cancer Patient Mar 20
New minor risk - Share price stability Mar 20
Atossa Therapeutics Regain Compliance with Nasdaq Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2) Mar 19
Less than half of directors are independent Mar 15
Atossa Therapeutics Appoints Tessa Cigler to Its Board of Directors Mar 13
Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans Mar 07
Atossa Therapeutics, Inc. Announces First Patient Dosed with Selective Estrogen Receptor Modulator in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment Feb 23
Forecast to breakeven in 2026 Dec 31
Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director Dec 04
Atossa Therapeutics, Inc. Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial Nov 21
Atossa Therapeutics, Inc. Appoints Jonathan Finn to Its Board of Directors Nov 12
Atossa Therapeutics, Inc. Appoints Jonathan Finn to Its Board of Directors Nov 10
We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate Nov 08
Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group Oct 31
Atossa Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Sep 29
Insufficient new directors Aug 11
Atossa Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023 Aug 09
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements Jul 14
Atossa Therapeutics, Inc. Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial Jul 11
New minor risk - Share price stability Jun 29
Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial Jun 29
Atossa Therapeutics, Inc. (NasdaqCM:ATOS) announces an Equity Buyback for $10 million worth of its shares. Jun 28
Atossa Therapeutics, Inc. Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 Evangeline Clinical Trial Evaluating (Z-Endoxifen as A Neoadjuvant Treatment for Er+ / Her2- Breast Cancer Jun 13
Atossa Therapeutics, Inc. Announces Executive Changes Jun 02
Price target decreased by 7.5% to US$4.63 May 24
Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth Apr 26
We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate Jan 09
Price target decreased to US$5.00 Nov 16
Price target decreased to US$5.00 Nov 13
Atossa Therapeutics, Inc. (NasdaqCM:ATOS) agreed to acquire 19.99% equity in Dynamic Cell Therapies, Inc. for $5 million. Nov 03
Atossa Therapeutics, Inc. (NasdaqCM:ATOS) agreed to acquire 19.99% equity in Dynamic Cell Therapies, Inc. for $5 million. Nov 02
Atossa Therapeutics, Inc. Appoints Richard Graydon as Interim Chief Medical Officer Oct 26
Atossa Therapeutics, Inc. Receives Authorization from FDA to Initiate Its Phase 2 Study of Neoadjuvant (Z)-Endoxifen in Premenopausal Women with Er+/Her2- Breast Cancer Oct 25
Atossa Therapeutics: Still Gets An 'Incomplete' Rating Oct 11
Atossa Therapeutics Receives Letter from NASDAQ Regarding Minimum Bid Price Requirement Oct 10
We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely Sep 25
Atossa Therapeutics, Inc. Appoints Dr. Paul Wabnitz to its Scientific Advisory Board Aug 19
Atossa Therapeutics GAAP EPS of -$0.05 Aug 08
Atossa Therapeutics, Inc. Announces Dosing Completed in Part C of Atossa’s Phase 1/2a Study of AT-H201 in Healthy Volunteers Jul 29
Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth May 12
Insufficient new directors Apr 27
Atossa Therapeutics, Inc. Announces Completion of Participants Enrollment in Part B of its Phase 1/2a Clinical Study of AT-H201 in Australia, Consisting of Multiple Ascending Dose Cohorts in Healthy Participants Apr 21
Atossa Therapeutics, Inc., Annual General Meeting, May 13, 2022 Apr 12
No longer forecast to breakeven Mar 03
Price target decreased to US$6.38 Feb 03
Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201 Jan 19
Forecast to breakeven in 2024 Jan 01
Atossa Therapeutics Begins Enrollment of Phase 2 Clinical Study of Oral Endoxifen in Sweden Dec 23
A First Assessment On Atossa Therapeutics Dec 10
We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate Dec 02
Atossa Therapeutics: Diversification Into COVID Makes Sense In A Variants World Sep 22
Atossa Therapeutics Receives Approval from Swedish Ethics Review Authority to Initiate A Phase 2 Clinical Study of Oral Endoxifen Sep 03
Atossa Therapeutics (NASDAQ:ATOS) Is In A Strong Position To Grow Its Business Jul 17
Independent Director notifies of intention to sell stock Jul 08
Atossa Therapeutics: Hope Springs Eternal Jun 30
Atossa Therapeutics to be included in the Russell 2000, 3000 indexes Jun 16
Atossa Therapeutics Receives Approval from Swedish Regulators to Initiate Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density Jun 12
Price target increased to US$7.50 Jun 10
Atossa Therapeutics Announces Final Data from Phase 2 Endoxifen Breast Cancer Study Primary Endpoint Met: 65.1% Reduction in Biomarker Ki-67; Secondary Endpoint Met: Endoxifen Safe and Well Tolerated Jun 10
Atossa Therapeutics to Release Final Data from Phase 2 Study of Endoxifen Administered to Breast Cancer Patients Prior to Surgery At A Webinar At 8 Am Pacific Time on June 9, 2021 Jun 08
Atossa reaches a two-year high ahead of data readout for breast cancer therapy Jun 07
Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans Apr 02
Atossa Therapeutics, Inc. Announces Receipt of FDA Safe to Proceed Letter for Treatment of an Ovarian Cancer Patient with Oral Endoxifen Under Expanded Access Pathway Mar 13
Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19 Feb 26
Atossa updates on single-patient study for Endoxifen Feb 04
Atossa Therapeutics, Inc.'s Phase 2 Endoxifen Breast Cancer Study Produces Substantially Positive Results Allowing Study to Be Halted Early Feb 03
Atossa halts Endoxifen breast cancer study after positive data Feb 02
New 90-day high: US$1.87 Jan 23
Atossa Therapeutics prices ~$25M direct offering, stock -23% PM Jan 06
Atossa Therapeutics prices $14M registered direct offering Dec 17
Atossa Therapeutics, Inc. has completed a Composite Units Offering in the amount of $20 million. Dec 10
New 90-day low: US$0.87 Dec 10
We're A Little Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate Dec 10
Atossa Therapeutics plummets 38% after it raises $20M in public offering Dec 09
Atossa Therapeutics EPS in-line Nov 13
Atossa Therapeutics Announces Preliminary Results from Phase 1 Clinical Study Showing Safety and Tolerability of At-301 Nasal Spray Being Developed for Covid-19 Nov 11
Safety data on COVID-19 nasal spray fails to lift Atossa, down 6% Nov 10
New 90-day low: US$1.37 Nov 10
Prévisions de croissance des bénéfices et des revenus NasdaqCM:ATOS - Estimations futures des analystes et données financières antérieures (USD Millions ) Date Recettes Les revenus Flux de trésorerie disponible Cash from Op Moy. Nombre d'analystes 12/31/2026 54 3 -27 -26 3 12/31/2025 N/A -32 N/A -28 4 12/31/2024 N/A -25 N/A -26 4 6/30/2024 N/A -26 -19 -19 N/A 3/31/2024 N/A -30 -19 -19 N/A 12/31/2023 N/A -30 -21 -21 N/A 9/30/2023 N/A -30 -20 -20 N/A 6/30/2023 N/A -32 -21 -21 N/A 3/31/2023 N/A -28 -23 -23 N/A 12/31/2022 N/A -27 -21 -21 N/A 9/30/2022 N/A -24 -20 -20 N/A 6/30/2022 N/A -21 -18 -18 N/A 3/31/2022 N/A -22 -17 -17 N/A 12/31/2021 N/A -21 -16 -16 N/A 9/30/2021 N/A -28 -16 -16 N/A 6/30/2021 N/A -26 -16 -16 N/A 3/31/2021 N/A -23 -13 -13 N/A 12/31/2020 N/A -22 -12 -12 N/A 9/30/2020 N/A -13 -11 -11 N/A 6/30/2020 N/A -13 -10 -10 N/A 3/31/2020 N/A -16 -10 -10 N/A 12/31/2019 N/A -17 -9 -9 N/A 9/30/2019 N/A -17 -9 -9 N/A 6/30/2019 N/A -17 -9 -9 N/A 3/31/2019 N/A -25 -9 -9 N/A 12/31/2018 N/A -23 -9 -9 N/A 9/30/2018 N/A -23 -8 -8 N/A 6/30/2018 N/A -22 -8 -8 N/A 3/31/2018 N/A -11 N/A -7 N/A 12/31/2017 N/A -11 N/A -7 N/A 9/30/2017 N/A -11 N/A -6 N/A 6/30/2017 N/A -9 N/A -4 N/A 3/31/2017 N/A -6 N/A -4 N/A 12/31/2016 N/A -6 N/A -5 N/A 9/30/2016 0 -6 N/A -8 N/A 6/30/2016 0 -10 N/A -12 N/A 3/31/2016 0 -12 N/A -14 N/A 12/31/2015 0 -13 N/A -14 N/A 9/30/2015 0 -13 N/A -13 N/A 6/30/2015 0 -13 N/A -12 N/A 3/31/2015 0 -13 N/A -11 N/A 12/31/2014 0 -12 N/A -11 N/A 9/30/2014 0 -12 N/A -10 N/A 6/30/2014 0 -12 N/A -10 N/A 3/31/2014 0 -11 N/A -10 N/A 12/31/2013 1 -11 N/A -9 N/A
Afficher plus
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: ATOS devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: ATOS devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: ATOS devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: ATOS ne devrait pas générer de revenus l'année prochaine.
Croissance élevée des revenus: ATOS ne devrait pas générer de revenus l'année prochaine.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de ATOS devrait être élevé dans 3 ans
Découvrir les entreprises en croissance Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
